Objectives: This study aimed to describe the impact of vaccination and the role of humoral responses on post-COVID-19 syndrome 1 year after the onset of SARS coronavirus type 2 (CoV-2).Methods: This prospective study was conducted through interviews to investigate post-COVID-19 syndrome 6 and 12 months after disease onset in all adult in- and outpatients with COVID-19 at Udine Hospital (March-May 2020). Vaccination status and two different serological assays to distinguish between response to vaccination (receptor-binding domain (RBD) SARS-CoV-2 IgG) and/or natural infection (non-RBD-SARS-CoV-2 IgG) were also assessed.Results: A total of 479 patients (52.6% female; mean age: 53 years) were interviewed 13.5 months (standard deviation: 0.6 mo...
Background: Vasculitis patients are at increased risk of negative outcome of a COVID-19 infection, b...
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causativ...
SARS-CoV-2 is a novel coronavirus that is the causative agent of coronavirus infectious disease 2019...
Objectives: This study aimed to describe the impact of vaccination and the role of humoral responses...
Objectives: This study aimed to describe the impact of vaccination and the role of humoral responses...
Objectives: To assess the prevalence of and factors associated with post-coronavirus disease 2019 (C...
Background: The duration of anti-SARS-CoV-2-antibody detectability up to 12 months was examined in i...
Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vacci...
Background: Symptoms of post-acute sequelae of COVID-19 (PASC) may improve following SARS-CoV-2 vacc...
Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vacci...
Background and objectives: Antibody to SARS-CoV-2 develops both after natural infection with SARS-Co...
Background: Emerging data support detectable immune responses for months after severe acute respirat...
International audienceBackground: Assessment of the kinetics of SARS-CoV-2 antibodies is essential i...
Background: Vasculitis patients are at increased risk of negative outcome of a COVID-19 infection, b...
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causativ...
SARS-CoV-2 is a novel coronavirus that is the causative agent of coronavirus infectious disease 2019...
Objectives: This study aimed to describe the impact of vaccination and the role of humoral responses...
Objectives: This study aimed to describe the impact of vaccination and the role of humoral responses...
Objectives: To assess the prevalence of and factors associated with post-coronavirus disease 2019 (C...
Background: The duration of anti-SARS-CoV-2-antibody detectability up to 12 months was examined in i...
Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vacci...
Background: Symptoms of post-acute sequelae of COVID-19 (PASC) may improve following SARS-CoV-2 vacc...
Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vacci...
Background and objectives: Antibody to SARS-CoV-2 develops both after natural infection with SARS-Co...
Background: Emerging data support detectable immune responses for months after severe acute respirat...
International audienceBackground: Assessment of the kinetics of SARS-CoV-2 antibodies is essential i...
Background: Vasculitis patients are at increased risk of negative outcome of a COVID-19 infection, b...
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causativ...
SARS-CoV-2 is a novel coronavirus that is the causative agent of coronavirus infectious disease 2019...